Previous close | 96.03 |
Open | 95.49 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 95.33 - 96.50 |
52-week range | 47.80 - 101.24 |
Volume | |
Avg. volume | 2,380 |
Market cap | 807.537M |
Beta (5Y monthly) | 1.62 |
PE ratio (TTM) | 0.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, April 25, 2024--KKR and Blackstone Real Estate Income Trust, Inc. ("BREIT") today announced a definitive agreement for funds managed by KKR to acquire a portfolio of 19 purpose-built student housing properties from BREIT for approximately $1.64 billion.
STOCKHOLM & LONDON, April 23, 2024--Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
NEW YORK, April 17, 2024--KKR & Co. Inc. (NYSE: KKR) announced today that it plans to release its financial results for the first quarter 2024 on Wednesday, May 1, 2024, before the opening of trading on the New York Stock Exchange.